User profiles for C. Pott
 | Christiane PottVerified email at med2.uni-kiel.de Cited by 16479 |
[HTML][HTML] A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
…, G Ott, RM Parwaresch, C Pott… - … England Journal of …, 2006 - Mass Medical Soc
Background The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma
is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more …
is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more …
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a …
…, E Hoster, AM Staiger, M Szczepanowski, C Pott… - The lancet …, 2015 - thelancet.com
Background Follicular lymphoma is a clinically and genetically heterogeneous disease, but
the prognostic value of somatic mutations has not been systematically assessed. We aimed …
the prognostic value of somatic mutations has not been systematically assessed. We aimed …
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
…, M Nakao, J Droese, S Lüschen, C Pott… - Blood, 2006 - ashpublications.org
Adult patients with acute lymphoblastic leukemia (ALL) who are stratified into the standard-risk
(SR) group due to the absence of adverse prognostic factors relapse in 40% to 55% of the …
(SR) group due to the absence of adverse prognostic factors relapse in 40% to 55% of the …
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as …
…, R Repp, S Hermann, A Hänel, B Metzner, C Pott… - Blood, 2004 - ashpublications.org
In follicular lymphoma (FL) and mantle cell lymphoma (MCL) the monoclonal antibody rituximab
may improve the prognosis when combined with chemotherapy. This was investigated …
may improve the prognosis when combined with chemotherapy. This was investigated …
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German …
…, G Jaenke, H Bodenstein, A Junker, C Pott… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: The study was initiated to obtain epidemiologic data and information on anatomic
and histologic distribution, clinical features, and treatment results in patients with primary …
and histologic distribution, clinical features, and treatment results in patients with primary …
Na+–Ca2+exchange in the regulation of cardiac excitation–contraction coupling
H Reuter, C Pott, JI Goldhaber… - Cardiovascular …, 2005 - academic.oup.com
… Different animal models with increased and reduced levels of expression of NCX have
been employed to study these effects on E–C coupling and we will review their results in the …
been employed to study these effects on E–C coupling and we will review their results in the …
Neural substrates of aggression and flight in the cat
A Siegel, CB Pott - Progress in neurobiology, 1988 - Elsevier
262 262 262 262 264 265 265 266 268 269 27O 270 270 271 272 272 272 272 273 273
273 273 273 273 274 274 275 275 275 275 275 275 276 276 276 276 276 276 276 277 …
273 273 273 273 274 274 275 275 275 275 275 275 276 276 276 276 276 276 276 277 …
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell …
…, W Klapper, E Macintyre, MH Delfau-Larue, C Pott… - The Lancet, 2016 - thelancet.com
Background Mantle cell lymphoma is characterised by a poor long-term prognosis. The
European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-…
European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-…
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine …
…, M Dreyling, HP Böck, R Repp, H Wandt, C Pott… - Blood, 2006 - ashpublications.org
In follicular lymphoma (FL) and mantle cell lymphoma (MCL) the monoclonal antibody
rituximab (R) improves the prognosis when combined with chemotherapy. The present study …
rituximab (R) improves the prognosis when combined with chemotherapy. The present study …
[HTML][HTML] Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma
Background Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as
monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% …
monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% …